GenomeWeb’s Post

📊Market Highlights: Monday, January 8, 2024 Stock futures exhibit a mixed trend on Monday, with investors keeping a keen eye on upcoming inflation data and big bank earnings later in the week. Top Gainers: Ambrx Biopharma (AMAM): Soars 103% after Johnson & Johnson's acquisition announcement, setting the stage for a transformative all-cash merger at $28 per share, totaling around $2 billion. Closing expected in 1H24; accounting treatment to be determined. American Eagle Outfitters (AEO): Surges 13%, hitting new 52-week highs on robust Q4 revenue growth of approximately 8%. Raised Q4 outlook to low double digits, citing a four-point positive contribution from the 53rd week. Operating profit now expected at around $130M. Harpoon Therapeutics (HARP): Witnesses an impressive surge, exceeding 100%, following Merck's agreement to acquire the cancer drugmaker for approximately $23 per share in cash, totaling ~$680M. Heron Therapeutics (HRTX): Surges following a partnership with CrossLink Life Sciences, aiming to expand the sales network for the ZYNRELEF® extended-release solution. Crocs (CROX): Soars by 12% post-positive guidance update, expecting a record 2023 revenue of approximately $3.95 billion, reflecting an 11% YoY increase. Q4 revenue to grow over 1%, with full-year 2023 non-GAAP operating margin projected to exceed 27%. Top Losers: Boeing (BA): Falls over 9% after a 737-9 Max plane accident, leading the FAA to temporarily ground 171 planes. Aerospace supplier Spirit AeroSystems (SPR) also experiences a 15% decrease. Solo Brands (DTC): Plunges 34% after revising FY2023 revenue outlook lower and appointing Christopher Metz as the new President, CEO, and Director. Dada Nexus (DADA): Drops 26% after revealing suspicious practices during a routine audit, estimating potential overstatements in revenues and halting guidance until further notice. Stay tuned for more market insights. 📌 #stockmarkets #financenews #investing #marketanalysis #stockstowatch #businessnews #stockmarketinsights #markettrends #investmentnews #stockmarketupdates #marketwatch #marketresearch #nilooferfinancialnews #niloofermarketviews

From pure investing point of view, it could well be that #Pfizer overpaid for its recent acquisitions: the price tag of Seegene Technologies and Seattle Genetics ($43 billion each) stood out (https://lnkd.in/ghBs6bE5). || One good example of #overpaying for acquisition is #disney buying #fox #movieStudio and related assets.

Bespoke posts on X: These are the 38 stocks in the S&P 1500 that are up 100%+ on the year with six trading days left. Who had Abercrombie & Fitch $ANF on their list of top performers at the start of the year? It's currently up more than any other stock in the index with a YTD gain of nearly 300%. Link: https://lnkd.in/g5iqGBmd My take: If you think ANF had impressive gains this year, come into my biotech universe and check out gains in Soleno Therapeutics (SLNE), Gyre Therapeutics (GYRE), EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and a bunch more biotechs that doubled and quadrupled from their bottom and were great to trade this year. Anyway, have fun looking at the list below, good to know in case one of your relatives annoys you this holiday season about how much money they made in the stock market. 😁

This biotech high-dividend stock is beating S&P 500 Dividend #investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen (NASDAQ: #AMGN) has demonstrated strong performance, surpassing the average return of the S&P 500. Since initiating dividend payouts in 2011, AMGN shares have outperformed the S&P 500, with a return of 382.28% compared to the index’s 292.76%. https://lnkd.in/g3vpjSc7

InVivo (NASDAQ: NVIV) Stock Soars Over 130% Following Recent Volatility: What’s Behind the Surge? https://lnkd.in/dVX4hG_u #invivo #NASDAQ #stockmarketnews #BusinessNews #News #NewsAlert

Alkermes Lags Q2 Earnings Estimates https://ift.tt/mSTNj8C Alkermes (NASDAQ: ALKS) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items. read more via Benzinga - Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals https://ift.tt/t5oXglY July 24, 2024 at 03:42PM

In the dynamic world of biotech investments, Mesoblast Ltd's stock has encountered a swift reversal, dropping by 10% today after an impressive previous surge of 71%. 📉🧫 Despite today's downturn, the tide may turn for Mesoblast Ltd in the face of their planned Biologics License Application refiling next quarter and the recent positive FDA engagement. 💡 Investor Insights: - Mesoblast's stock saw substantial growth, outpacing the S&P/ASX 300 Index. - Today's decline may represent a strategic profit-taking step by investors following the stock's leap. - Looking forward, the company anticipates a strong stance in its FDA application prospects. For long-term investors, today's market reaction might offer a vantage point for strategic decision-making. Keep a close watch on Mesoblast Ltd in the upcoming quarter! 🚀💼 Read the full analysis of the Mesoblast stock's recent performance and what it signals to investors: https://lnkd.in/eQiRDpSP #Mesoblast #Biotech #StockMarket #Investment #FDA #BiologicsLicense #MarketAnalysis #Finance

$MOLA - 15 for 1 Split can cause some disturbance for MOLECULIN BIOTECH: About 17.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MOLECULIN BIOTECH recorded a loss per share of 1.31. The entity had not issued any dividends in recent years. The firm had 15:1 split on the 2nd of January 2024. https://lnkd.in/gZ23-XGb #stocks #stocktwits #thematic_portfolio

Thousand Oaks-based Atara Biotherapeutics announced June 17 that it will be undergoing a 1-for-25 reverse stock split which will become effective at 12:01 a.m. June 20. A reverse stock split consolidates the number of existing shares of stock into fewer, higher-priced shares. For example, Atara shares closed at 42 cents per share on June 16, dropping 16% over the course of the trading day. If the reverse stock split occurred at 12:01 after that closing price, shares would be worth roughly $10.50 per share. https://lnkd.in/gZFC-gdE

$72C1 - Earnings call is projected this week.: About 60.0% of the company shares are owned by institutions such as pension funds. The company has Price-to-Book (P/B) ratio of 0.63. In the past many companies with similar price-to-book ratios have beat the market. Eiger BioPharmaceuticals recorded a loss per share of 2.12. The entity had not issued any dividends in recent years. The firm had 30:1 split on the 8th of December 2023. https://lnkd.in/gWsyCuxV #stocks #stocktwits #thematic_portfolio